FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
August 01 2018 - 5:21PM
FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today
announced that it will report second quarter 2018 financial results
on Tuesday, August 7, 2018, after market close, and will host a
conference call to discuss financial results and provide a business
update at 5:00 p.m. ET (2:00 p.m. PT).
Conference Call and Audio Webcast Interested
parties may access a live audio webcast of the conference call via
the investor section of the FibroGen website, www.fibrogen.com. It
is recommended that listeners access the website 15 minutes prior
to the start of the call to download and install any necessary
audio software. A replay of the webcast will be available shortly
after the call for a period of two weeks. To access the replay,
please dial (888) 843-7419 (domestic) or (630) 652-3042
(international), and use passcode 47339190#.
Dial-In InformationLive (U.S./Canada): (888)
771-4371Live (International): (847) 585-4405Confirmation number:
47339190
About FibroGen FibroGen, Inc., headquartered in
San Francisco, with subsidiary offices in Beijing and Shanghai, is
a leading biopharmaceutical company discovering and developing a
pipeline of first-in-class therapeutics. The company applies
its pioneering expertise in hypoxia-inducible factor (HIF),
connective tissue growth factor (CTGF) biology, and clinical
development to advance innovative medicines for the treatment of
anemia, fibrotic disease, and cancer. Roxadustat, the company’s
most advanced product candidate, is an oral small molecule
inhibitor of HIF prolyl hydroxylase activity, completing worldwide
Phase 3 clinical development for the treatment of anemia in chronic
kidney disease (CKD), with a New Drug Application (NDA) currently
under review in China by the State Drug Administration (SDA).
Roxadustat is in Phase 3 clinical development in the U.S. and
Europe and in Phase 2/3 development in China for anemia associated
with myelodysplastic syndromes (MDS). Pamrevlumab, an
anti-CTGF human monoclonal antibody, is advancing towards Phase 3
clinical development for the treatment of idiopathic pulmonary
fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2
trial for Duchenne muscular dystrophy (DMD). FibroGen is also
developing a biosynthetic cornea in China. For more information,
please visit www.fibrogen.com.
ContactFibroGen, Inc.Karen L. BergmanVice
President, Investor Relations and Corporate Communications1 (415)
978-1433kbergman@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024